Clinical Trial Detail

NCT ID NCT03330405
Title Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

progesterone-receptor positive breast cancer

transitional cell carcinoma

ovarian cancer

prostate cancer

estrogen-receptor positive breast cancer

Advanced Solid Tumor

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

Avelumab + Talazoparib

Age Groups: adult senior

No variant requirements are available.